The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.
"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said.
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.
